The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

被引:110
作者
Wang, JS
Ruan, Y
Taylor, RM
Donovan, JL
Markowitz, JS
De Vane, CL
机构
[1] Med Univ S Carolina, Inst Psychiat, Dept Psychiat & Behav Sci, Lab Drug Disposition & Pharmacogenet, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA
关键词
P-glycoprotein; 9-OH-risperidone; risperidone;
D O I
10.1017/S1461145704004390
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P-glycoprotein (P-gp) in the brain capillary endothelial cell limits the entry of many drugs into the brain. Our previous in-vitro study using ATPase as a marker of P-gp activity suggested that risperidone might be effectively transported by P-gp. In the present study, we compared the concentrations of risperidone and its major pharmacologically active metabolite 9-hydroxyrisperidone (9-OH-risperidone), in plasma, brain and various other tissues between abcb1ab-/- knockout mice which are functionally devoid of P-gp in their blood-brain barrier vs. FVB wild-type mice. One hour after intraperitoneal injection of 4 mug/g risperidone, the brain concentrations and ratios of brain: plasma concentrations of risperidone (13.1-fold and 12-fold respectively, p < 0.05) and 9-OH-risperidone (29.4-fold and 29-fold respectively, p < 0.01) were significantly higher in the abcb1ab-/- mice than those in the FVB mice. These results indicate that P-gp in the blood-brain barrier significantly influences the brain concentrations of risperidone and 9-OH-risperidone by limiting their CNS access.
引用
收藏
页码:415 / 419
页数:5
相关论文
共 16 条
[1]   In vitro P-glycoprotein affinity for atypical and conventional antipsychotics [J].
Boulton, DW ;
DeVane, CL ;
Liston, HL ;
Markowitz, JS .
LIFE SCIENCES, 2002, 71 (02) :163-169
[2]   Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs [J].
Doan, KMM ;
Humphreys, JE ;
Webster, LO ;
Wring, SA ;
Shampine, LJ ;
Serabjit-Singh, CJ ;
Adkison, KK ;
Polli, JW .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :1029-1037
[3]  
Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12
[4]   The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors [J].
Kim, RB ;
Fromm, MF ;
Wandel, C ;
Leake, B ;
Wood, AJJ ;
Roden, DM ;
Wilkinson, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :289-294
[5]   Mechanisms of action of atypical antipsychotic drugs: A critical analysis [J].
Kinon, BJ ;
Lieberman, JA .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :2-34
[6]   Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview [J].
Schinkel, AH ;
Jonker, JW .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (01) :3-29
[7]   P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs [J].
Schinkel, AH ;
Wagenaar, E ;
Mol, CAAM ;
vanDeemter, L .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2517-2524
[8]   Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins [J].
Schinkel, AH ;
Mayer, U ;
Wagenaar, E ;
Mol, CAAM ;
vanDeemter, L ;
Smit, JJM ;
vanderValk, MA ;
Voordouw, AC ;
Spits, H ;
vanTellingen, O ;
Zijlmans, JMJM ;
Fibbe, WE ;
Borst, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :4028-4033
[9]   DISRUPTION OF THE MOUSE MDR1A P-GLYCOPROTEIN GENE LEADS TO A DEFICIENCY IN THE BLOOD-BRAIN-BARRIER AND TO INCREASED SENSITIVITY TO DRUGS [J].
SCHINKEL, AH ;
SMIT, JJM ;
VANTELLINGEN, O ;
BEIJNEN, JH ;
WAGENAAR, E ;
VANDEEMTER, L ;
MOL, CAAM ;
VANDERVALK, MA ;
ROBANUSMAANDAG, EC ;
TERIELE, HPJ ;
BERNS, AJM ;
BORST, P .
CELL, 1994, 77 (04) :491-502
[10]   The cognitive efficacy of atypical antipsychotics in schizophrenia [J].
Sharma, T ;
Mockler, D .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (02) :12S-19S